Glioblastoma multiforme (GBM) is one of the most aggressive cancers with a low overall survival rate. The treatment of GBM is challenging due to the presence of the blood–brain barrier (BBB), which hinders drug delivery. Invasive procedures alone are not effective at completely removing such tumors. Hence, identifying the crucial pathways and biomarkers for the treatment of GBM is of prime importance. We conducted this study to identify the pathways associated with GBM. We used The Cancer Genome Atlas (TCGA) GBM genomic dataset to identify differentially expressed genes (DEGs). We investigated the prognostic values of the guanine nucleotide-binding protein G(i) alpha subunit (GNAI) family of genes in GBM using a Chinese Glioma Genome Atlas (CGGA) dataset. Within this dataset, we observed the association in the tumor microenvironment between the gene expression of GNAI subunit 3 (GNAI3) and a poor prognosis. MetaCore and gene ontology (GO) analyses were conducted to explore the role of GNAI3 in co-expressed genes and associated signaling pathways using a transcript analysis. Notable pathways included “Cytoskeleton remodeling regulation of actin cytoskeleton organization by the kinase effectors of Rho GTPases” and “Immune response B cell antigen receptor (BCR) pathway”. A single-cell analysis was used to assess GNAI3 expression in GBM. The results demonstrated that GNAI family genes, specifically GNAI3, were significantly associated with carcinogenesis and malignancy in GBM patients. Our findings suggest that the GNAI3 gene holds potential as a prognostic biomarker for GBM.

L. barbarum is a Chinese herbal medicine used to treat male infertility. The aim of this study was to investigate glycogen synthase kinase-3 (GSK-3) phosphorylation involving sperm capacitation and the mechanisms by which L. barbarum polysaccharide (LBP) mixtures protect sperm. During capacitation at 60 or 90 min, the level of the sperm GSK-3 pTyr216/279 phosphoprotein significantly increased, whereas the levels of GSK-3 pS21 decreased but those of pS9 increased significantly. Treatment with 2 mg/mL LBP3M without exposure to iron slightly increased pGSK-3α S21 toward capacitation but significantly decreased pGSK-3α S9. The ability of 4 mg/mL LBP3M to prevent insults from 40 μM iron and exert posttranslational effects on sperm proteins was tested. Without iron insult, the relative phosphorylation of GSK-3 at pTyr216/279 significantly increased threefold after 60 min of incubation with 2 mg/mL LBP3M under normal glucose conditions. These effects were determined after incubation with a higher dose (4 mg/mL) of the LBP3M mixture, but relative pGSK-3 α / β at Tyr216/279 were decreased. In summary, treatment with the 4 mg/mL LBP3M mixture has protective effects on sperm motility upon exposure to excess iron and potentially acts as a glucose source, modulating the posttranslational signals of GSK-3 phosphorylation to promote capacitation.

Esta investigación se llevó a cabo para determinar el efecto de la exposición al macho cabrío sobre la respuesta al estro, el inicio del estro permanente, la tasa de ovulación, la tasa de concepción y la tasa de preñez en cabras sincronizadas con esponjas de acetato de medroxiprogesterona (MAP). Se colocaron esponjas dentro de la vagina durante quince días en grupos aislados y expuestos a machos. Después de retirar la esponja, se observaron continuamente las actividades estrales. El intervalo entre la retirada de la esponja y el inicio del estro permanente fue de 32.3±10 h (18-51 h) y 45.2±10.9 h (27-51 h) en el grupo de machos aislados y expuestos respectivamente (p0.05). Los embarazos fueron confirmados por ultrasonido en el día 35 después del apareamiento, que fueron 93%, fue y 69% en el grupo expuesto y aislado de machos, respectivamente (p>0.05). Sobre la base de la evidencia, se infirió que la exposición repentina al macho después de la extracción de la esponja provocó un inicio del estro notablemente más temprano, mientras que la exposición continua al macho no pudo mostrar un impacto significativo en las tasas de concepción y preñez en comparación con el grupo aislado.

Objective: Therapeutic drug monitoring (TDM) indicators have been suggested to predict overall outcome responses to olanzapine (OLZ) treatments in terms of efficacy and metabolic syndrome. This study aimed to investigate whether paraoxonase-1 (PON-1) activity can be used to predict schizophrenia patient outcomes. Methods: Schizophrenic patients ( N = 50) aged between 20 and 65 years who received OLZ treatment were recruited, and their Positive and Negative Syndrome Scale scores, PON-1 activity, and olanzapine drug levels normalized by dose (OLZ/D) and its metabolite N-desmethyl-olanzapine (DMO), together with biochemical parameters, were determined. Results: PON-1 activity and OLZ/D were significantly correlated in 50 patients (correlation coefficient, r = 0.355; p = 0.0115). There was also a statistically significant correlation between the ratio of PON-1 activity normalized by homocysteine (Hcy) and OLZ/D (correlation coefficient r = 0.361; p = 0.01) and a significant negative correlation between the ratio of PON-1 activity normalized by Hcy and triglyceride/high-density lipoprotein (TG/HDL; correlation coefficient r = −0.328; p = 0.02). Conclusions: PON-1 activity can be used as an alternative tool for monitoring TDM through the measurement of OLZ together with its metabolite, DMO, to identify patients who have higher activity. Those who show an optimal response or who have lower activity might have greater cardiometabolic risk under long-term olanzapine treatment. Longitudinal monitoring is warranted to confirm such observations.